BLOG

biospace

Sanofi and CytoReason Target IBD in Expanded Collaboration (Updated)

If data is the new oil, CytoReason is one of its barons. Combining all available information about a disease – literature, data sets, all data types – the company builds computational disease models utilized by its pharma partners to help them determine which drug avenues to pursue next.